Failure of mycophenolate mofetil therapy in primary refractory nephrotic syndrome
Baglio, V.; Pecci, G.; Gangemi, C.; Barresi, G.; Morabito, S.; Pierucci, A.
Journal of Nephrology 19(6): 819-824
2006
ISSN/ISBN: 1121-8428 PMID: 17173257 Document Number: 595873
Mycophenolate mofetil (MMF) has been suggested as a promising therapeutic agent in the treatment of idiopathic nephrotic syndrome. Two patients with persistent nephrotic syndrome, secondary to minimal change disease and idiopathic membranous nephropathy, respectively, who were steroid-, cyclophosphamide- and cyclosporine-resistant, were treated with MMF during a 6-12-month period. In these cases there was no beneficial effect from treatment with MMF. Therapy was stopped after 6 months in case I and after 12 months in case 2 due to the persistence of proteinuria.